In this study, we aimed to explore the immunomodulatory effect of the HDAC inhibitor chidamide on circulating PD-1(+) cells from patients with PTCL, as well as its correlation with treatment response. This evidence concerns the gene PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma.